VKORC1 rs17150687: Understanding Warfarin Sensitivity
The rs17150687 variant is a genetic marker located within the VKORC1 gene, which plays a critical role in how the body processes the anticoagulant medication warfarin. Research indicates that this variant is associated with variations in the maintenance dose requirements needed to achieve therapeutic levels of anticoagulation.
What each genotype means
Increased warfarin sensitivity
This genotype is associated with increased sensitivity to warfarin and typically requires lower maintenance doses to achieve therapeutic anticoagulation. Because individual responses vary based on other genetic factors and clinical characteristics, you should discuss your specific dosing requirements with your clinician or pharmacist.
This genotype is more common in populations of East Asian ancestry and less frequent in those of African ancestry.
Intermediate warfarin sensitivity
This genotype is associated with an intermediate response to warfarin compared to other genetic profiles. Your maintenance dose requirements may differ from those with the AA or GG genotypes, so it is important to consult with your healthcare provider to determine the appropriate dose for your clinical needs.
This genotype is observed across various global populations with varying frequencies depending on ancestral background.
Typical warfarin dose requirement
This genotype is generally associated with higher warfarin dose requirements compared to those carrying the A allele. As warfarin dosing is complex and influenced by multiple factors including other genes and clinical variables, please work closely with your medical team to manage your therapy.
This genotype is most common in populations of African ancestry and is less frequent in populations of East Asian ancestry.
What is the rs17150687 Variant?
The rs17150687 variant is a single nucleotide polymorphism (SNP) situated within the VKORC1 gene, which is located on chromosome 16. Specifically, this variant is classified as an intronic regulatory variant. In genetics, introns are non-coding regions of a gene that do not provide instructions for making proteins directly, but they often contain regulatory elements that influence how much of a protein is produced. Because rs17150687 sits in a regulatory region, it is hypothesized to affect the expression levels of the VKORC1 enzyme. By altering the efficiency of gene transcription, this variant may indirectly influence the physiological response to drugs that target this specific enzyme pathway.
The Role of the VKORC1 Gene
The VKORC1 gene provides the instructions for creating the vitamin K epoxide reductase complex subunit 1 enzyme. This enzyme is essential for the vitamin K cycle, a biological process that allows the body to recycle vitamin K, which is necessary for the production of blood-clotting factors. Warfarin, a widely prescribed anticoagulant, works by inhibiting this specific enzyme. By blocking the activity of VKORC1, warfarin reduces the body's ability to produce clotting factors, thereby thinning the blood and preventing dangerous clots. Because VKORC1 is the direct target of warfarin, any genetic variation that changes the amount or activity of this enzyme can significantly alter how a patient responds to the medication.
Research and Clinical Associations
Scientific research has identified VKORC1 as a primary genetic determinant of warfarin dose requirements. While much of the literature focuses on promoter variants like -1639G>A, intronic variants such as rs17150687 are also studied for their potential to influence dosing. Evidence for rs17150687 is currently considered limited compared to more established markers. Studies suggest that individuals carrying certain alleles may require different maintenance doses to maintain a safe and effective therapeutic range. However, it is important to note that warfarin dosing is complex and influenced by many factors, including age, body weight, diet, and other medications. Genetic testing for this variant is not a standalone diagnostic tool; rather, it is one piece of a larger clinical puzzle used to help clinicians optimize therapy.
Population Frequency
The frequency of the rs17150687 variant varies significantly across different ancestral groups. Current data indicates a minor allele frequency of approximately 0.38 in European populations and approximately 0.10 in African populations. These differences highlight the importance of considering ancestry when evaluating the potential impact of genetic variants on drug response. Because the prevalence of specific alleles changes based on geographic and ancestral background, the clinical relevance of this SNP may differ from one patient to another.
Managing Your Genetic Information
If you have received information about your VKORC1 genotype, it is essential to understand that this data should only be interpreted in the context of your overall health and medical history. You cannot use this information to adjust your medication dosage on your own. Warfarin therapy requires careful monitoring by a healthcare professional, such as a doctor or a pharmacist, who will use blood tests like the International Normalized Ratio (INR) to ensure your dose is safe. If you are concerned about how your genetics might affect your response to warfarin, bring your genetic report to your next appointment. Your clinician can explain how this information fits into your personalized treatment plan and whether it warrants any changes to your current management strategy.
How common is this variant?
The minor allele frequency for rs17150687 is approximately 0.38 in European populations and 0.10 in African populations.
Frequently asked questions
Does having this variant mean I cannot take warfarin?
No, having this variant does not mean you cannot take warfarin. It simply means your body may process the drug differently, which your doctor will account for when determining your appropriate dose.
Should I change my warfarin dose based on my genotype?
Absolutely not. Never change your medication dosage without direct instruction from your healthcare provider, as doing so can lead to serious health risks like bleeding or clotting.
Is this the only gene that affects warfarin?
No, warfarin response is influenced by several genes, most notably CYP2C9 and VKORC1. Clinicians often look at a combination of genetic and non-genetic factors to guide dosing.
Where can I get tested for this variant?
Genetic testing for warfarin response is typically ordered by a physician if they believe it will help guide your clinical care. You should discuss the necessity and utility of such testing with your doctor.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs17150687?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VKORC1
The VKORC1 -1639G>A promoter variant reduces vitamin K epoxide reductase subunit 1 expression, requiring lower therapeutic warfarin maintenance doses to prevent bleeding complications.
This VKORC1 variant is a clinically useful marker for sensitivity to warfarin and related vitamin-K-antagonist dosing, with direct implications for medication safety.
Promoter variant in VKORC1 influencing warfarin sensitivity and dosing requirements.
Located in VKORC1, this missense variant (p.Val66Met) is associated with warfarin resistance requiring elevated therapeutic dosages.
Intronic regulatory variant in VKORC1 in high linkage disequilibrium with rs9923231, dictating clinical warfarin dosing requirements.
This variant is a well-established marker in the VKORC1 gene often used in studies regarding warfarin sensitivity and dosing.